Pneumococcal capsular polysaccharide serotype 19A (CPS19A) (CPS19A)

Pneumococcal capsular polysaccharide serotype 19A is a complex carbohydrate polymer that constitutes the outermost protective layer of the Streptococcus pneumoniae bacterium (PubMed, 2015). It functions as a primary virulence factor by shielding the pathogen from the host's immune system, specifically by inhibiting opsonophagocytosis and complement-mediated killing (PMC, 2014). Serotype 19A has emerged as a significant cause of invasive pneumococcal disease globally, particularly following the introduction of early conjugate vaccines that did not cover this specific serotype, leading to its increased prevalence through serotype replacement (CDC, 2022). It is a key antigenic component in modern multivalent pneumococcal vaccines, including conjugate (PCV13, PCV15, PCV20, PCV21) and polysaccharide (PPSV23) formulations (FDA, 2023). These vaccines work by eliciting a humoral immune response, producing antibodies that recognize the 19A polysaccharide and promote bacterial clearance (WHO, 2019). Targeting this polysaccharide is vital for reducing the burden of diseases such as pneumonia, meningitis, and febrile bacteremia (StatPearls, 2023).

Other names

Streptococcus pneumoniae serotype 19A capsular polysaccharide19A pneumococcal polysaccharideS. pneumoniae CPS19APneumococcal polysaccharide serotype 19A

Induces active immunity by stimulating the production of serotype-specific opsonizing antibodies that facilitate phagocytosis and killing of Streptococcus pneumoniae (FDA, 2023; WHO, 2019).